Orthofix Medical's Q2 sales exceeded estimates at $188.6M, a 7.7% increase, with Bone Growth Therapies and U.S. Spine Fixation driving growth.
Orthofix Medical (OFIX) shares rose 0.7% as Q2 sales surpassed Wall Street estimates at $188.6M, a 7.7% increase. The company reported a $36M loss (95¢/share) and expects net sales to be $790-795M in 2024, with free cash flow positivity by Q4 2024. Orthofix's Bone Growth Therapies and U.S. Spine Fixation contributed to the growth, while Global Orthopedics net sales increased by 5%.
May 07, 2024
3 Articles